Reuters logo
BRIEF-Biomarin presents interim data of phase 1/2 study of BMN 250 for treatment of Sanfilippo B syndrome
September 6, 2017 / 3:30 PM / 3 months ago

BRIEF-Biomarin presents interim data of phase 1/2 study of BMN 250 for treatment of Sanfilippo B syndrome

Sept 6 (Reuters) - Biomarin Pharmaceutical Inc

* Biomarin presents interim data of phase 1/2 study of BMN 250 for treatment of Sanfilippo B syndrome (MPS IIIB) at 13th international congress of inborn errors of metabolism (ICIEM) 2017

* Says ‍interim trial data indicates that ICV-administered bmn 250 was well-tolerated by Sanfilippo B patients​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below